sickle cell anemia
NICE Recommends Vertex, CRISPR Therapeutics' Casgevy for Sickle Cell Under Managed Access Deal
The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.
HHS Calls Vertex's Case for Fertility Program a 'Distraction,' Urges Court to Rule in Its Favor
HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run afoul of anti-kickback laws.
Vertex Gains Rights to Orna Therapeutics' Drug Delivery Tech in $1.07B Deal
Vertex aims to further bolster its gene-editing therapy pipeline by using Orna's lipid nanoparticle delivery technologies during the three-year collaboration.
CBO Outlines Budgetary Considerations for Policies Focused on Sickle Cell Disease Gene Therapy
The Congressional Budget Office said policies to increase treatment uptake could affect Medicaid, Social Security, and other government programs.
Gates Foundation Invests up to $50M to Support Tessera Therapeutics' In Vivo SCD Gene Therapy
Tessera and the foundation will jointly fund development of the gene therapy for sickle cell disease.